PCSK9 Inhibition After Heart Transplantation

Trial ID or NCT#

NCT03537742

Status

recruiting iconRECRUITING

Purpose

The focus of this study is to test the safety and efficacy of the PCSK9 inhibitor, alirocumab when administered early after heart transplantation (HT).The main objective of this project is to test the safety and impact on cardiac allograft vasculopathy (CAV) of alirocumab when given early after HT.

Official Title

PCSK9 Inhibition After Heart Transplantation

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Heart Transplant recipient
Exclusion Criteria:
  1. - impaired liver function
View All Criteria
Show Less

Investigator(s)

William Fearon, MD
William Fearon, MD
Interventional cardiologist, Cardiologist
Professor of Medicine (Cardiovascular Medicine)

Contact us to find out if this trial is right for you.

Contact

Study Team
650-724-2883

SEND MESSAGE

View on ClinicalTrials.gov